MannKind Corporation reports it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agreement with Sanofi.

Pursuant to the agreement, MannKind previously received a $150 million upfront payment and is eligible to earn up to $725 million in further development, regulatory, and sales milestones, and is also eligible to receive a share of profits on sales of the Afrezza insulin treatment that MannKind developed.